12 protocols meet the specified criteria.
-
Establishment of a National Biorepository to Advance Studies of Immune-Related Adverse Events
-
Reaching Rural Cancer Survivors Who Smoke Using Test-Based Cessation Interventions
-
Managed Access Program (MAP) to provide access to CTL019, for acute lymphoblastic leukemia (ALL) in diffuse large b-cell lymphoma (DLBCL) patients with out of specification leukapheresis product and/or manufactured tisagenlecleucel out of specification for commercial release
-
AALL1621 - A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518, IND# 133494) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)
-
Molecular Analysis for Combination Therapy Choice (ComboMATCH)
-
REACH Study: Real-world Evidence to Advance Multi-Cancer Early Detection Health Equity (REACH/Galleri-Medicare study)
-
A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
-
Expanded Access Protocol (EAP) for Subjects Receiving Lisocabtagene Maraleucel that is Nonconforming for Commercial Release
-
Expanded access to commercially out-of-specification brexucabtagene autoleucel for the treatment of adult patients diagnosed with an FDA approved labeled indication
-
A Phase 1, Open-Label, Dose-escalation, and Dose-Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of SNDX-5613 in Combination with Intensive Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemias Harboring Alterations in Lysine-specific Methyltransferase 2A (KMT2A/MLL), Nucleophosmin1 (NPM1), and Nucleoporin 98 (NUP98) Genes
-
Prospective Evaluation of Xerava (Eravacycline) Prophylaxis in Hematological Malignancy Patients with Prolonged Neutropenia
-
A Multicenter Phase II Study of Subcutaneous Blinatumomab for Treatment of Adult Patients with CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)